(RTTNews) - CytoSorbents Corp. (CTSO), a medical device company specializing in blood purification technologies, Friday announced a $6.25 million stock financing and an agreement with Avenue Capital Group to reduce debt and extend its loan maturity.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.
